TRYP THERAPEUTICS INC. Financials Tryp Therapeutics Inc. OTC Markets
Equities
TRYP.F
CA89854F1062
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0476 USD | -2.76% |
|
+32.50% | +39.88% |
| Mar. 08 | Tryp Therapeutics Inc. announced that it has received AUD 3.39 million in funding | CI |
| Feb. 05 | Tryp Therapeutics Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023 | CI |
Valuation
| Fiscal Period: August | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 21.78 | 13.9 | 5.872 | 5.785 | - | - |
| Enterprise Value (EV) 1 | 21.78 | 13.9 | 5.872 | 5.785 | 5.785 | 5.785 |
| P/E ratio | -3.21 x | -1.65 x | -1.3 x | -2 x | -3 x | -6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 48,406 | 84,244 | 90,332 | 96,419 | - | - |
| Reference price 2 | 0.4500 | 0.1650 | 0.0650 | 0.0600 | 0.0600 | 0.0600 |
| Announcement Date | 12/22/21 | 12/13/22 | 12/29/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: August | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -7.288 | -7.364 | -5.246 | -5.096 | -5.603 | -5.883 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -8.255 | -7.495 | -5.267 | -5.096 | -5.603 | -5.883 |
| Net income 1 | -8.255 | -7.495 | -5.267 | -5.096 | -5.603 | -5.883 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.1400 | -0.1000 | -0.0500 | -0.0300 | -0.0200 | -0.0100 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/22/21 | 12/13/22 | 12/29/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: August | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -2.752 | -3.01 | -1.549 | - | -2.104 | -1.616 | -1.266 | - | -1.593 | -1.131 | -1.163 | -1.328 | -1.517 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -2.77 | -3.001 | -1.559 | - | -2.17 | -1.634 | -1.287 | -0.7838 | -1.69 | -1.161 | -1.163 | -1.328 | -1.517 |
| Net income 1 | -2.77 | -3 | -1.559 | -0.7499 | -2.17 | -1.634 | -1.287 | -0.6558 | -1.69 | -1.161 | -1.163 | -1.328 | -1.517 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.0400 | -0.0500 | -0.0300 | -0.0100 | -0.0300 | -0.0200 | -0.0100 | - | -0.0100 | -0.0100 | -0.0100 | -0.0100 | -0.0100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/22/21 | 1/28/22 | 4/29/22 | 7/28/22 | 12/13/22 | 1/25/23 | 4/28/23 | 7/31/23 | 12/29/23 | 2/5/24 | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: August | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 12/22/21 | 12/13/22 | 12/29/23 | - | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.06
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.77% | 42.75B | |
| +47.70% | 41.61B | |
| +12.24% | 41.34B | |
| -8.83% | 26.59B | |
| +7.44% | 25.49B | |
| -23.01% | 18.12B | |
| +30.56% | 12.24B | |
| -1.82% | 11.76B | |
| +8.35% | 11B |
- Stock Market
- Equities
- TRYP Stock
- TRYP.F Stock
- Financials Tryp Therapeutics Inc.
